Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday.
The analysts wrote, “. We are reiterating our Overweight rating and $135 price target. We believe that early trends from the launch are in line with our expectations. We are staying with Alnylam as a top franchise pick in 2019, and are not worried about launch trends that are really too early to read into in a new market it is building. Not surprising, investors paid the closest attention to the new start number that was 125 patients after about 7 weeks of launch. We think that this number of new starts is solid for hATTR amyloidosis, a disease for which there haven’t been many therapies to treat these patients. We also think that Alnylam has been very clear that this is a market that the new players would have to build.””
A number of other equities analysts have also recently commented on ALNY. BidaskClub raised shares of Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, November 2nd. Stifel Nicolaus raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $95.00 to $125.00 in a research report on Monday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $149.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $152.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, August 13th. Finally, ValuEngine cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 7th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $142.94.
ALNY stock opened at $72.41 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22. Alnylam Pharmaceuticals has a one year low of $70.43 and a one year high of $153.99. The firm has a market cap of $8.69 billion, a price-to-earnings ratio of -13.36 and a beta of 2.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $22.66 million. During the same period last year, the firm earned ($1.34) earnings per share. The company’s revenue for the quarter was down 87.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -7.28 earnings per share for the current fiscal year.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the sale, the chief operating officer now owns 1,916 shares of the company’s stock, valued at $229,920. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at about $137,000. Opera Trading Capital bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $137,000. Mutual of America Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 98.5% in the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 960 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Alnylam Pharmaceuticals by 600.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 1,953 shares during the period. Finally, IPG Investment Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $217,000. 90.37% of the stock is owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Recommended Story: Preferred Stock
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.